Pharmaceutical probiotics for the treatment of anaerobic and other infections

Anaerobe

Volumn 3, Issue 2-3, 1997, Pages 73-78

  McFarland, L V ^a,b,c   Elmer, G W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Service de Pharmacologie   (France)

^c NONE   (United States)

Author keywords

Antibiotic side effects; Diarrhea; Probiotics; Vaginitis

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BACTERIOCIN; HYDROGEN PEROXIDE; LACTIC ACID; METRONIDAZOLE; VANCOMYCIN; YOGHURT;

ANAEROBIC INFECTION; BACTERIAL FLORA; BIOLOGICAL THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; ENTEROCOCCUS FAECALIS; FEMALE; HUMAN; IMMUNOMODULATION; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BIFIDUS; LACTOBACILLUS CASEI; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PRIORITY JOURNAL; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS; TRAVELLER DIARRHEA; VAGINITIS;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM BIFIDUM; CLOSTRIDIUM DIFFICILE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS; ROTAVIRUS; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS;

EID: 0031126399     PISSN: 10759964     EISSN: None     Source Type: Journal    
DOI: 10.1006/anae.1996.0062     Document Type: Conference Paper

References (52)

1. Adams J., Barret C., Barret-Bellet C., Benedetti E., Caledini A., Darchen P. et al. Essais cliniques contrôlés en double insu de l'ultra-levure lyophilisée. Ètude multicentrique par 25 médecins de 388 cas. Gazette Médicale de France. 84:1977;2072-2078.
2. Elmer G. W., Surawicz C. M., McFarland L. V. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA. 275:1996;870-876.
3. McFarland L. V., Elmer G. W. Biotherapeutic agents: past, present, and future. Microecology and Therapy. 23:1995;46-73.
4. Service R. F. Antibiotics that resist resistance. Science. 270:1995;724-727.
5. Biller J. A., Katz A. J., Flores A. F., Buie T. M., Gorbach S. L. Treatment of recurrentClostridium difficileLactobacillus. J Pediatr Gastroenterol Nutr. 21:1995;224-226.
6. Isolauri E., Juntunen M., Rautanen T., Sillanaukee P., Koivula T. A humanLactobacillusLactobacillus Casei. Pediatrics. 88:1991;90-97.
7. McFarland L. V., Surawicz C. M., Greenberg R. N., Fekety R., Elmer G. W., Moyer K. A. et al. A randomized placebo-controlled trial ofSaccharomyces boulardiiClostridium difficile. JAMA. 271:1994;1913-1918.
8. Mitra A. K., Rabbani G. H. A double-blind, controlled trial of bioflorin (Streptococcus FaeciumVibrio choleraeEscherichia coli. Gastroenterology. 99:1990;1149-1152.
9. Saavedra J. M., Bauman N. A., Oung I., Perman J. A., Yolken R. H. Feeding ofBifidobacterium bifidumStreptococcus thermophilus. Lancet. 344:1994;1046-1049.
10. McGroarty J. A. Probiotic use of lactobacilli in the human female urogenital tract. FEMS Immunol Med Microbiol. 6:1993;251-264.
11. Hilton E., Isenberg H. D., Alperstein P., France K., Borenstein M. T. Ingestion of yoghurt containingLactobacillus acidophilus. Ann Intern Med. 116:1992;353-988.
12. Surawicz C. M., Elmer G. W., Speelman P., McFarland L. V., Chinn J., van Belle G. Prevention of antibiotic-associated diarrhea bySaccharomyces boulardii. Gastroenterology. 96:1989;981-988.
13. Nord C. E., Edlund C. Impact of antimicrobial agents on human intestinal microflora. J Chemother. 2:1990;218-237.
14. Bacher K., Schaeffer M., Lode H., Nord C. E., Borner K., Koeppe P. Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother. 30:1992;365-375.
15. McFarland L. V., Surawicz C. M., Greenberg R. N., Elmer G. W., Moyer K. A., Melcher S. A. et al. Prevention of β-lactam-associated diarrhea bySaccharomyces boulardii. Am J Gastroenterol. 90:1995;439-448.
16. Høverstad T., Midtvedt T., Bøhmer T. Short-chain fatty acids in intestinal content of germfree mice monocontaminated withEscherichia coliClostridium difficile. Scand J Gastroenterol. 20:1985;373-380.
17. Que J. U., Casey S. W., Hentges D. J. Factors responsible for increased susceptibility of mice to intestinal colonization after treatment with Streptomycin. Infect Immun. 53:1986;116-123.
18. Rao S. S.C., Edwards C. A., Austen C. J., Bruce C., Read N. W. Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology. 94:1988;928-932.
19. Cherbut C., Ferre J. P., Corpet D. E., Ruckebusch Y., Delort-Laval J. Alterations of intestinal microflora by antibiotics. Effects of fecal excretion, transit time, and colonic motility in rats. Dig Dis Sci. 36:1991;1729-1734.
20. Folks D. G., Kinney F. C. The role of psychological factors in gastrointestinal conditions. A review pertinent to DSM-IV. Psychosomatics. 33:1992;257-270.
21. Bowden T. A., Mansberger A. R., Lykins L. E. Pseudomembraneous enterocolitis: mechanism of restoring floral homeostasis. Am Surg. 4:1982;178-183.
22. Tvede M., Task-Madsen J. Bacteriotherapy for chronic relapsingClostridium difficile. Lancet. I:1989;1156-1160.
23. McFarland L. V., Bernasconi P. Saccharomyces boulardii. Microbial Ecol Health Dis. 6:1993;157-171.
24. Gorbach S. L., Chang T. -W., Goldin B. Successful treatment of relapsingClostridium difficileLactobacillus. Lancet. ii:1987;1519.
25. Gotz V., Romankiewicz J. A., Moss J., Murray H. W. Prophylaxis against ampicillin-associated diarrhea with aLactobacillus. Am J Hosp Pharm. 36:1979;754-757.
26. Tankanow R. M., Ross M. B., Ertel I. J., Dickinson D. G., McCormick L. S., Garfinkel J. F. A double-blind, placebo-controlled study of the efficacy of lactinex in the prophylaxis of amoxicillin-induced diarrhea. DICP, Ann Pharmacother. 24:1990;382-384.
27. Settel E. Lactobacillus acidophilus. Clin Med. 69:1962;700-704.
28. Beck C., Nechelles H. Beneficial effects of administration ofLactobacillus acidophilus. Am J Gastroenterol. 35:1961;522-530.
29. Colombel J. F., Cortot A., Neut C., Romond C. Yoghurt withBifidobacterium longum. Lancet. 2:1987.
30. Marteau P., Pochart P., Bouhnik Y., Zidi S., Goderel I., Rambaud J. -C. Survival ofLactobacillus acidophilusBifidobacterium. Gastroenterol Clin Biol. 16:1992;25-28.
31. Roach S., Tannock G. W. Indigenous bacteria that influence the number ofSalmonella typhimurium. Can J Microbiol. 26:1980;408-411.
32. Chapoy P. Treatment of acute infantile diarrhea: controlled trial ofSaccharomyces boulardii. Ann Pediatr (Paris). 32:1985;561-563.
33. Cetina-Sauri G., Basto G. S. Evaluación terapéutica deSaccharomyces boulardii. Tribuna Médica. 56:1989;111-115.
34. Höchter W., Chase D., Hagenhoff G. Saccharomyces boulardii. Münchener Medizinische Wochenschrift. 132:1990;188-192.
35. Wunderlich P. F., Braun L., Fumagalli I., D'Apuzzo V., Heim F., Karly M. et al. Double-blind report on the efficacy of lactic acid-producing enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res. 17:1989;333-338.
36. Reid G., Bruce A. W., McGroarty J. A., Cheng K. -J., Costerton J. W. Is there a role forLactobacilli. Clin Microbiol Rev. 3:1990;335-344.
37. Larsen B. Vaginal flora in health and disease. Clin Obstet Gynecol. 36:1993;107-121.
38. Fredericsson, B. Englund, K. Weintraub, L. Olund, A. Nord, C. E. 1989, Abstract. 4th Eur. Congr. Clin. Microbiol. abstr. no. 179.
39. Van der Weiden R. M., van der Meijden W. I., Bogchelman D. H., Polderman A. M. Treatment failure in trichomoniasis and persistence of the parasite afterLactobacillus. Eur J Obstet Gynecol Reprod Biol. 34:1990;171-178.
40. Hilton E., Rindos P., Isenberg H. D. Lactobacillus. J Clin Microbiol. 33:1995;1433.
41. Goldin B. R., Gorbach S. L., Saxelin M., Barakat S., Gualtieri L., Salminen S. Survival ofLactobacillus. Dig Dis Sci. 37:1992;121-128.
42. Klein S. M., Elmer G. W., McFarland L. V., Surawicz C. M., Levy R. H. Recovery and elimination of the biotherapeutic agent,Saccharomyces boulardii. Pharm Res. 18:1993;1615-1619.
43. Blehaut H., Massot J., Elmer G. W., Levy R. H. Disposition kinetics ofSaccharomyces boulardii. Biopharm Drug Dispos. 10:1989;353-364.
44. Pothoulakis C., Kelly C. P., Joshi M. A., Gao N., O'Keane C. J., Castagliuolo I., LaMont J. T. Saccharomyces boulardiiClostridium difficile. Gastroenterology. 104:1993;1108-1115.
45. Silva M., Jacobus N. V., Deneke C., Gorbach S. L. Antimicrobial substance from a humanLactobacillus. Antimicrob Agents Chemother. 31:1991;1231-1233.
46. Fuller R. Probiotics in human medicine. Gut. 32:1991;439-442.
47. Kennedy M. J., Volz P. A. Ecology ofCandida albicansCandida. Infect Immun. 49:1985;654-663.
48. Bernet M. F., Brassart D., Neeser J. R., Servin A. L. Lactobacillus acidophilus. Gut. 35:1994;483-489.
49. Itoh K., Freter R. Control ofEscherichia coliLactobacilli. Infect Immun. 57:1989;559-565.
50. Kaila M., Isolauri E., Soppi E., Virtanen E., Laine S., Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a humanLactobacillus. Pediatr Res. 32:1992;141-144.
51. Buts J. P., Bernasconi P., Vaerman J. P., Dive C. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated withSaccharomyces boulardii. Dig Dis Sci. 35:1990;251-256.
52. Wilson K. H., Perini F. Role of competition for nutrients in suppression ofClostridium difficile. Infect Immun. 56:1988;2610-2614.